AKT1 and cancer: These results demonstrated that imatinib inhibited PI3K, AKT, and mTOR phosphorylation, indicating this suppression effect on signaling pathway (Figure 4A), corroborating previous studies that reported the inhibition effect of imatinib on the PI3K/AKT/mTOR pathway in various cancers 26.